The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

The Long-Term Safety and Efficacy of Intrathecal Therapy Using Sufentanil in Chronic Intractable Non-Malignant Pain

  • Monsivais, Jose Jesus (Hand and Microsurgery Center of El Paso, Orthopedics and Rehabilitation, Texas Tech University Health Science Center (TTUHSC)) ;
  • Monsivais, Diane Burn (Hand and Microsurgery Center of El Paso, Orthopedics and Rehabilitation, Texas Tech University Health Science Center (TTUHSC))
  • Received : 2014.06.11
  • Accepted : 2014.06.13
  • Published : 2014.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

This report describes the long term safety and efficacy of intrathecal therapy using Sufentanil for the management of chronic intractable neuropathic pain in 12 chronic pain patients. Standardized psychological screening was used to determine treatment suitability. Evaluation data included the Visual Analog Scale (VAS), Wong-Baker Faces Scale, Brief Pain Inventory (BPI), Disability of Arm, Shoulder, and Hand (DASH), McGill Quality of Life Questionnaire, and complications (granulomas, toxicity, withdrawal, or deaths). SPSS version 18 was used for data analysis. Pre- and post- treatment BPI measures and pain scale scores showed a statistically significant difference. There were no complications directly related to drug toxicity, nor drug withdrawals, granulomas, or deaths. Intrathecal therapy with Sufentanil therapy offers a good treatment alternative for those cases that have failed both surgery and standard pain treatment. Strict patient selection based on psychological screening, control of co-morbidities, a proper pain management may contribute to successful outcome.

Keywords

References

  1. Monsivais JJ, Robinson K. Psychological profile and work status of a predominantly Hispanic worker's compensation population with chronic limb pain. Hand (N Y) 2008; 3: 352-8. https://doi.org/10.1007/s11552-008-9123-1
  2. Lieberman IH. Disc bulge bubble: spine economics 101. Spine J 2004; 4: 609-13. https://doi.org/10.1016/j.spinee.2004.09.001
  3. Nguyen TH, Randolph DC, Talmage J, Succop P, Travis R. Long-term outcomes of lumbar fusion among workers' compensation subjects: a historical cohort study. Spine (Phila Pa 1976) 2011; 36: 320-31.
  4. Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. Intrathecal therapy for cancer and non-cancer pain. Pain Physician 2011; 14: 219-48.
  5. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med 2006; 7: 251-9. https://doi.org/10.1111/j.1526-4637.2006.00155.x
  6. Stuppy DJ. The faces pain scale: reliability and validity with mature adults. Appl Nurs Res 1998; 11: 84-9. https://doi.org/10.1016/S0897-1897(98)80229-2
  7. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-21. https://doi.org/10.1016/j.jpain.2007.09.005

Cited by

  1. Intrathecal administration of human bone marrow mesenchymal stem cells genetically modified with human proenkephalin gene decrease nociceptive pain in neuropathic rats vol.13, pp.1744-8069, 2017, https://doi.org/10.1177/1744806917701445
  2. Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use pp.1432-0932, 2017, https://doi.org/10.1007/s00586-017-5387-x